Please assess the completion status of the following clinical trial:

Trial Title: Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed acute myeloid leukemia or acute lymphoblastic leukemia:~  * Relapsed \>= 1 time OR refractory disease:~    * Patients who fail primary induction therapy or who relapse after achieving complete remission are eligible if they have received =\< 3 prior courses of induction/reinduction therapy~* Relapsed \>= 1 time OR refractory disease~* Patients who fail primary induction therapy or who relapse after achieving complete remission are eligible if they have received =\< 3 prior courses of induction/reinduction therapy~* No active CNS leukemia~* ECOG performance status 0-2~* AST and ALT =\< 5 times upper limit normal (ULN)~* Alkaline phosphatase =\< 5 times ULN~* Bilirubin =\< 2.0 mg/dL~* Creatinine =\< 2.0 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* LVEF \>= 45% by MUGA or ECHO~* No active, uncontrolled infection~* No other life-threatening illness~* No mental deficits and/or psychiatric history that would preclude study compliance~* No active graft-vs-host disease~* Recovered from all prior therapies~* At least 24 hours since prior hydroxyurea, steroids, imatinib mesylate, arsenic trioxide, interferon, or leukapheresis for blast count control~* At least 4 weeks since prior stem cell transplantation (autologous or allogeneic)~* At least 4 days since prior growth factors~* At least 3 weeks since prior chemotherapy, except for non-aplasia producing treatments (e.g., low-dose cyclophosphamide, hydroxyurea, interferon, imatinib mesylate, mercaptopurine, thalidomide, azacitidine, or decitabine)~* No prior flavopiridol~* No other concurrent chemotherapy, radiotherapy, or immunotherapy~* No acute promyelocytic leukemia (M3)~* No hyperleukocytosis with \> 50,000 blasts/mm\^3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive flavopiridol IV over 30 minutes on days 1, 2, and 3. Patients receive cytarabine IV continuously over 72 hours beginning on day 6 and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.

Based on this trial design, predict the completion outcome and termination type (if applicable).